Advanced SearchNewsfeedFollowed Companies

Juno's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Juno is a biopharmaceutical company that researches and develops cellular immunotherapies for the treatment of cancer.

Ju... Read more

Estimated Annual Revenue

Estimated Employees

Lothar Germeroth's photo - Managing Director of Juno

Managing Director

Lothar Germeroth

CEO Approval Rating

79/100

OVERVIEW

Founded:

2013

Headquarters:

Seattle, Washington

Status:

PrivateSubsidiary of Bristol Myers Squibb Co

Industry Sector:

Biotechnology,
Pharmaceuticals

SIC Code:

2836NAICS listing »

2834NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $106M a good estimate for Juno's revenue?

I don't know

Trending News for Juno and Juno's Competitors

Today 8:42 AM

Reuters

Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19

Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, join... See more »

April 2, 2020

GeekWire

The search for a COVID-19 cure: Amgen and Adaptive Biotech partner in quest for new drug

Pharmaceutical giant Amgen is aiming to develop a new drug to treat and prevent COVID-19, using insig... See more »

Today 9:34 AM

BioPortfolio

Pfizer wins EU approval for MabThera biosimilar

The drug will be available to treat certain cancers and autoimmune conditions... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Novartis is the top competitor of Juno. Novartis was founded in 1996, and its headquarters is in Basel, Basel-City. Like Juno, Novartis also operates in the Pharmaceuticals field. Novartis has 103,251 more employees than Juno.

Amgen is seen as one of Juno's top competitors. Amgen was founded in Thousand Oaks, California} in 1980. Like Juno, Amgen also works within the Biotechnology field. Compared to Juno, Amgen generates $23.3B more revenue.

Jounce Therapeutics is Juno's #3 rival. Jounce Therapeutics's headquarters is in Cambridge, Massachusetts, and was founded in 2012. Like Juno, Jounce Therapeutics also operates in the Biotechnology sector. Jounce Therapeutics generates 139% of Juno's revenue.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Lothar Germeroth

Managing Director

- -
663
$1.5B
$106M
1

Vasant Narasimhan

CEO

90/100
118,393
- -
$47.4B
2

Robert A. Bradway

Chairman & CEO

64/100
19,200
$19M
$23.4B
3

Richard Murray

President & CEO

85/100
115
$204.8M
$147.9M
4

Wang Chuncheng

CEO

70/100
56,000
$105.7M
$22.1B
5

Albert Bourla

Chairman & CEO

68/100
92,400
- -
$51.8B
6

Nick Leschly

President & CEO

80/100
764
$275.9M
$44.7M
7

Christophe Weber

President & CEO

72/100
49,578
$7.5B
$29.9B
8

Adi Hoess

CEO

66/100
53
$180.9M
$45.6M
9

Filippo Petti

CEO

87/100
82
$232.6M
$3.6M
10

Daniel O’Day

Chairman & CEO

74/100
11,000
$86.3M
$22.4B
The top 10 competitors in Juno's competitive set are Novartis, Amgen, Jounce Therapeutics, CR Pharmaceutical, Pfizer, bluebird bio, Takeda, Affimed, Celyad and Gilead. Together they have raised over 8.6B between their estimated 334.4K employees. Juno's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 17.9B. Juno has 663 employees and is ranked 8th among it's top 10 competitors. The top 10 competitors average 31,658.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION

-

-

Jul 2016

Source »
undisclosed
-
Abvitro, Inc.

Jan 2016

Source »
$78M
AbVitro is an immuno-oncology antibody discovery platform that allows for the discovery of cancer specific tumor infiltrating lymphocytes.
X-BODY Biosciences, Inc.

Jun 2015

Source »
$21M
X-BODY Biosciences is a biotechnology firm that focuses on discovery of monoclonal antibodies against novel therapeutic.

These are all the companies that Juno has acquired. Juno has acquired 3 companies and its latest acquisition was in Jul 2016.

Juno Funding History

Since Juno was founded in 2013, it has participated in 6 rounds of funding. In total Juno has raised $1.5B. Juno's last funding round was on Sep 2017 for a total of $31.1M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Sep 2017
$31.1M
Equity
Jun 2015
$896.8M
-
IPO
Dec 2014
$264.6M
-
Series B
Jul 2014
$134M
-
Series A
Apr 2014
$176M

ARCH Venture Partners

Total Funding: $1.5B

Since Juno was founded in 2013, it has participated in 6 rounds of funding. In total Juno has raised $1.5B. Juno's last funding round was on Sep 2017 for a total of $31.1M

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

JW Therapeutics focuses on developing cell-based immunotherapies for the treatment of cancer.
$90M
Mar 07, 2018
Series A
-

These are all the companies that Juno has invested in. Juno has invested 3 companies and its latest investment was in Jul 2016.

Juno News

December 16, 2019Global Legal Chronicle

Kettering Institute for Cancer Research and Juno Therapeutics v. Kite Pharma Inc.

Irell & Manella LLP advised Sloan Kettering Institute for Cancer Research and Juno Therapeutics on th... See more »
December 15, 2019MedCity News

Jury awards BMS subsidiary $752M in CAR-T patent infringement suit

A federal jury in California found that Kite Pharma - now part of Gilead Sciences - violated a patent... See more »
December 12, 2019FiercePharma

Kite Pharma, Juno duke it out in court over megamillion-dollar CAR-T patent

Behind the cell and gene therapy headlines-approvals, manufacturing snafus, new data-two of the indus... See more »
December 2, 2019Beckers Hospital Review

Juno Therapeutics co-founder starting new drug company

See more »
July 30, 2019STAT News

A mysterious startup launched with an impossibly ambitious rallying cry. Now its plans are coming into focus

Sana Biotechnology's early code name, FD Therapeutics, hints at the buzzy startup's aggressive vision... See more »
July 17, 2019BioCentury

Using CRISPR to edit TCRs, plus AAVs with synthetic promoters and AI for cancer diagnosis

See more »
January 10, 2019GeekWire

Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert

Things are a little on edge in Seattle's biotech scene after the Jan. 3 announcement that pharmaceuti... See more »

Juno Press Releases

November 7, 2017MarketersMedia

Featured Company News - US FDA Clears Sarepta Therapeutics' IND Application for GALGT2 Gene Therapy Program; Nationwide Children's Hospital Prepared to Initiate Phase-1/2a Clinical Trials for Patients with DMD

Research Desk Line-up: Juno Therapeutics Post Earnings CoverageLONDON, UK / ACCESSWIRE / November 7, ... See more »
August 19, 2017Blackbird

Kahn Swick & Foti, LLC Investigates the Officers and Directors of Juno Therapeutics, Inc. - JUNO

NEW ORLEANS, Aug. 18, 2017 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr.... See more »
June 14, 2017Business Wire

Court Decides It Lacks Jurisdiction Before FDA Approval Occurs

SEATTLE--(BUSINESS WIRE)--Court Decides It Lacks Jurisdiction Before FDA Approval Occurs... See more »
May 9, 2017Blackbird

Juno Therapeutics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

See more »
January 4, 2017Blackbird

Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

SEATTLE-(BUSINESS WIRE)-Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast i... See more »
December 15, 2016Blackbird

Federman & Sherwood Reminds Investors of the Securities Class Action Lawsuit Against Juno Therapeutics, Inc.

OKLAHOMA CITY-(BUSINESS WIRE)-On July 13, 2016, a class action lawsuit was filed in the United States... See more »
December 9, 2016Newswise

Fred Hutch to Hold Grand Opening of Bezos Family Immunotherapy Clinic

Leaders from Fred Hutch, Seattle Cancer Care Alliance and Juno Therapeutics will speak on immunothera... See more »

Juno Videos

Social Statistics

Headquarters

400 Dexter Avenue North Suite 1200

Seattle, Washington98109

206-582-1600

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Juno is a biopharmaceutical company that researches and develops cellular immunotherapies for the treatment of cancer. Juno was founded in 2013. Juno's headquarters is located in Seattle, Washington, USA 98109. It has raised 1.5B in 6 rounds. The late...

CEO

Juno's Managing Director, Lothar Germeroth, currently has an approval rating of 79%. Juno's primary competitors are Novartis, Amgen & Jounce Therapeutics.

Website

junotherapeutics.com

Frequently Asked Questions about Juno

  1. When was Juno founded?

    Juno was founded in 2013

  2. Who is Juno's CEO?

    Juno's CEO is Lothar Germeroth

  3. How much revenue does Juno generate?

    Juno generates $106M in revenue

  4. How much funding does Juno have?

    Juno has historically raised $1.5B in funding

  5. Where is Juno's headquarters?

    Juno's headquarters is in Seattle Washington, USA

  1. How many employees does Juno have?

    Juno has 663 employees

  2. What sector does Juno operate in?

    Juno is in Biotechnology, Pharmaceuticals

  3. Who are Juno's competitors?

    Juno's top competitors are Novartis, Amgen, Jounce Therapeutics

  4. Who has Juno invested in?

    Juno's has invested in companies such as JW Therapeutics
Stay up-to-date with the latest news on Juno